Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (51-60 of 199) with videos related to

Pageof 20
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 11, 2012
Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolismAtul B Shinagare, Yuka Okajima, Geoffrey R Oxnard, et al.
The Journal of Molecular Diagnostics : JMD|March 17, 2015
Enhanced ratio of signals enables digital mutation scanning for rare allele detectionElena Castellanos-Rizaldos, Cloud Paweletz, Chen Song, et al.
JAMA Network Open|March 23, 2022
Prevalence of UV Mutational Signatures Among Cutaneous Primary TumorsDouglas A Mata, Erik A Williams, Ethan Sokol, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 8, 2023
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-OsimertinibJulia K Rotow, Jessica K Lee, Russell W Madison, et al.
Scientific Reports|September 21, 2016
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLCHugo J W L Aerts, Patrick Grossmann, Yongqiang Tan, et al.
Scientific Reports|February 18, 2017
Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLCHugo J W L Aerts, Patrick Grossmann, Yongqiang Tan, et al.
Cancer|August 16, 2016
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy developmentBenjamin L Lampson, Mizuki Nishino, Suzanne E Dahlberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Screening for germline EGFR T790M mutations through lung cancer genotypingGeoffrey R Oxnard, Vincent A Miller, Mark E Robson, et al.
The Oncologist|September 28, 2013
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorsSarah B Goldberg, Geoffrey R Oxnard, Subba Digumarthy, et al.
The Journal of Liquid Biopsy|March 3, 2025
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use casesAakash Desai, Lincoln W Pasquina, Candice Nulsen, et al.
Pageof 20

Showing results (51-60 of 199) with videos related to

Sort By:
Pageof 20
Lung Cancer (Amsterdam, Netherlands)|September 11, 2012
Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolismAtul B Shinagare, Yuka Okajima, Geoffrey R Oxnard, et al.
The Journal of Molecular Diagnostics : JMD|March 17, 2015
Enhanced ratio of signals enables digital mutation scanning for rare allele detectionElena Castellanos-Rizaldos, Cloud Paweletz, Chen Song, et al.
JAMA Network Open|March 23, 2022
Prevalence of UV Mutational Signatures Among Cutaneous Primary TumorsDouglas A Mata, Erik A Williams, Ethan Sokol, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 8, 2023
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-OsimertinibJulia K Rotow, Jessica K Lee, Russell W Madison, et al.
Scientific Reports|September 21, 2016
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLCHugo J W L Aerts, Patrick Grossmann, Yongqiang Tan, et al.
Scientific Reports|February 18, 2017
Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLCHugo J W L Aerts, Patrick Grossmann, Yongqiang Tan, et al.
Cancer|August 16, 2016
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy developmentBenjamin L Lampson, Mizuki Nishino, Suzanne E Dahlberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Screening for germline EGFR T790M mutations through lung cancer genotypingGeoffrey R Oxnard, Vincent A Miller, Mark E Robson, et al.
The Oncologist|September 28, 2013
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorsSarah B Goldberg, Geoffrey R Oxnard, Subba Digumarthy, et al.
The Journal of Liquid Biopsy|March 3, 2025
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use casesAakash Desai, Lincoln W Pasquina, Candice Nulsen, et al.
Pageof 20